drugset / Trial / NCT00175045

Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis

NCT00175045

Phase 2 Completed 68 enrolled Takeda
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to compare the pharmacodynamics of intravenous (IV) lansoprazole to oral lansoprazole capsules, once daily (QD), in participants with erosive esophagitis.

Timeline

Start
2003-06
Primary completion
2003-10
Completion
2003-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lansoprazole Other / unclassified 30 mg Intravenous